Bromantane (Ladasten)

The practical verdict on Bromantane is that it is a reasonable adjunct for asthenic recovery and stress resilience in someone willing to accept gray-market sourcing, willing to use the compound intermittently rather than continuously (Nick's protocol is 30 mg morning, pulsed not daily), and not subject to any sport drug-testing regime. The Voznesenskaia 2010 trial signal is strong, even though the literature is single-country, single-funder, and the manufacturer let the only registered brand lapse. Related reports cover Modafinil, Selank, Semax, and Ashwagandha. Registration and evidence-breadth gaps remain limitations. It is meaningfully different from a classical stimulant; the manufacturer-walkaway pattern remains the main thing to watch.

✅ Best for: Knowledge workers and high-output executives running 30 mg pulsed in the morning (not daily) who want an actoprotector that does not feel like coffee or a classical stimulant; biohackers comfortable sourcing from research-chemical vendors with an HPLC certificate of analysis and willing to use the compound intermittently rather than continuously; users with low-baseline-alpha EEG patterns or post-burnout phenotype who tend to fall in the dual-mechanism responder cohort; people who have tried Modafinil and dislike the wakefulness-without-recovery feel; readers who want a peptide-adjacent stack with Selank or Semax and are aware that the long-term safety record is short.

❌ Avoid if: You are pregnant, lactating, under 18, on an MAOI, or competing in any tested sport (WADA Prohibited List S6.A since 1997, Burnat 1997, Docherty 2008); you have bipolar I, uncontrolled hypertension, or a history of stimulant-induced agitation; you stack high-dose dopaminergics (Modafinil, methylphenidate, amphetamines, L-DOPA, selegiline) without a careful interaction review; you are unwilling to source from a research-chemical vendor and not located in Russia where the brand is no longer manufactured; you want a Western RCT-backed intervention rather than a single-country evidence base; you are sensitive to dopaminergic agitation or insomnia and unwilling to dose only in the morning. Counterfeit and underdosed product is documented in 2025 European forensic surveillance (Vanhee 2025), so gray-market sourcing without HPLC verification is itself a contraindication.

Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.